ATAI Life Sciences BV

NASDAQ ATAI

Download Data

ATAI Life Sciences BV Revenue for the quarter ending March 31, 2024: USD 0.00

ATAI Life Sciences BV Revenue is USD 0.00 for the quarter ending March 31, 2024, a -100.00% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • ATAI Life Sciences BV Revenue for the quarter ending March 31, 2023 was USD 37.00 K, a 0.00% change year over year.
  • ATAI Life Sciences BV Revenue for the quarter ending March 31, 2022 was USD 0.00, a -100.00% change year over year.
  • ATAI Life Sciences BV Revenue for the quarter ending March 31, 2021 was USD 19.88 M, a 0.00% change year over year.
  • ATAI Life Sciences BV Revenue for the quarter ending March 31, 2020 was USD 0.00.
NASDAQ: ATAI

ATAI Life Sciences BV

CEO Mr. Christian Angermayer
IPO Date June 18, 2021
Location Germany
Headquarters Krausenstrasse 9-10, Berlin, Germany, 10117
Employees 83
Sector Healthcare
Industry Biotechnology
Description

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Similar companies

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

ITOS

Iteos Therapeutics Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email